Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Chief Financial Officer | February 04, 2020 | February 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date February 04, 2020 · Filed February 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,162 |
Reported balance
After 2020-02-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-26 · Grant · Acquired 3,000 · Balance 50,162 F1: Reflects the first vesting installment of RSUs granted on February 26, 2019. |
| Common StockSEC Table I · non-derivative | Direct | 49,281 |
Reported balance
After 2020-02-26 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-02-26 · Tax withholding · Disposed 881 · Balance 49,281 F2: Reflects an aggregate of 881 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on February 26, 2020. F3: Reflects the closing price of the ANIK common stock on February 26, 2020, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,700 |
Reported balance
After 2020-02-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-25 · Grant · Acquired 11,700 · Balance 11,700 F4: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the first vesting installment of RSUs granted on February 26, 2019.
F2: Reflects an aggregate of 881 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on February 26, 2020.
F3: Reflects the closing price of the ANIK common stock on February 26, 2020, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
F4: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2020 Filed Feb 27, 2020 23:49 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 881 | $42.25 | $37,222.25 |
DisclosureSEC source: 0001171843-20-001358 · ownership.xml · nonDerivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,281 F2 · shares: Reflects an aggregate of 881 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on February 26, 2020. F3 · price: Reflects the closing price of the ANIK common stock on February 26, 2020, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 23:49 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001358 · ownership.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,162 F1 · security: Reflects the first vesting installment of RSUs granted on February 26, 2019. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:49 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 11,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001358 · ownership.xml · derivative · entry 3 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 22:12 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 579 | $40.59 | $23,501.61 |
DisclosureSEC source: 0001171843-20-000783 · ownership.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,162 F1 · shares: Reflects an aggregate of 579 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested on February 4, 2020. F2 · price: Reflects the closing price of the ANIK common stock on February 4, 2020, the trading day on which the vesting of restricted shares gave rise to tax withholding obligations. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:40 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 20,000 | $59.71 | $1,194,200.00 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · nonDerivative · entry 3 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,741 F3 · security: On November 8, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung sold 20,000 shares in multiple trades ranging from $59.00 to $60.40, a portion of which sale covered the tax liability associated with the SARs exercise. The price reported above reflects the weighted average sale price. Ms. Cheung undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. F3 · price: On November 8, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung sold 20,000 shares in multiple trades ranging from $59.00 to $60.40, a portion of which sale covered the tax liability associated with the SARs exercise. The price reported above reflects the weighted average sale price. Ms. Cheung undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:40 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionStock Appreciation Rights · Derivative | 35,000 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · derivative · entry 4 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2020-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On November 6, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung exercised stock appreciation rights ("SARS") granted on January 26, 2010 vesting in four equal annual installments beginning January 26, 2011 and expiring on January 26, 2020. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:40 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 3,681 | $60.48 | $222,626.88 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · nonDerivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,741 F2 · security: Reflects 3,681 shares of common stock utilized to cover the exercise price of the above listed SARs award by the Reporting Person on November 6, 2019. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:40 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 35,000 | $6.36 | $222,600.00 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 6, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung exercised stock appreciation rights ("SARS") granted on January 26, 2010 vesting in four equal annual installments beginning January 26, 2011 and expiring on January 26, 2020. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:32 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 7,609 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001385 · ownership.xml · derivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,609 Underlying: Common Stock · 7,609 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:32 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001385 · ownership.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 14:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 607 | $38.10 | $23,126.70 |
DisclosureSEC source: 0001171843-19-000756 · ownership.xml · nonDerivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,422 F2 · shares: Reflects an aggregate of 607 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested in full on February 4, 2019. Read SEC document |
| February 03, 2019 Filed Feb 6, 2019 14:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 579 | $37.97 | $21,984.63 |
DisclosureSEC source: 0001171843-19-000756 · ownership.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,029 F1 · shares: Reflects an aggregate of 579 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested in full on February 3, 2019. Read SEC document |
| March 02, 2018 Filed Mar 2, 2018 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 7,788 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-18-001658 · formfour.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,788 Underlying: Common Stock · 7,788 shares Expires 2027-01-27 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000689 · formfour.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001206 · formfour.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-02-03 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionStock Option (Right to buy) · Derivative | 807 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · derivative · entry 9 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Exercise of 807 stock options granted on June 7, 2011 that were fully vested. F4 · derivative.expiration_date: Exercise of 807 stock options granted on June 7, 2011 that were fully vested. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionStock Option (Right to buy) · Derivative | 4,193 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · derivative · entry 8 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 4,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise of 4,193 stock options granted on June 7, 2011 that are fully vested. F3 · derivative.expiration_date: Exercise of 4,193 stock options granted on June 7, 2011 that are fully vested. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionStock Appreciation Rights · Derivative | 5,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · derivative · entry 7 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercise of stock appreciation rights ("SARS") granted on January 31, 2008, which vested in full on such date, and expiring on January 31, 2018. F1 · derivative.expiration_date: Exercise of stock appreciation rights ("SARS") granted on January 31, 2008, which vested in full on such date, and expiring on January 31, 2018. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 807 | $49.02 | $39,559.14 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 6 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,608 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 1,193 | $49.05 | $58,516.65 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 5 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,415 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 5,000 | $6.99 | $34,950.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 4 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Exercise of 4,193 stock options granted on June 7, 2011 that are fully vested. F4 · security: Exercise of 807 stock options granted on June 7, 2011 that were fully vested. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 2,000 | $49.01 | $98,020.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 3 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,117 | $49.20 | $54,956.40 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,608 F2 · security: Reflects 1,117 shares of common stock utilized to cover the exercise price of the above listed SARs award by the Reporting Person on February 22, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 5,000 | $10.99 | $54,950.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of stock appreciation rights ("SARS") granted on January 31, 2008, which vested in full on such date, and expiring on January 31, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:07 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-17-000586 · formfour.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2027-01-27 F1 · derivative.exercise_date: The stock options vest in three equal annual installments beginning January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.